CureVac/$CVAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CureVac
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Ticker
$CVAC
Sector
Primary listing
Employees
-
Headquarters
Website
CureVac Metrics
BasicAdvanced
$1.2B
5.38
$1.00
2.53
-
Price and volume
Market cap
$1.2B
Beta
2.53
52-week high
$5.72
52-week low
$2.37
Average daily volume
418K
Financial strength
Current ratio
6.172
Quick ratio
5.887
Long term debt to equity
5.312
Total debt to equity
6.145
Interest coverage (TTM)
589.30%
Profitability
EBITDA (TTM)
289.006
Gross margin (TTM)
94.85%
Net profit margin (TTM)
37.93%
Operating margin (TTM)
46.40%
Effective tax rate (TTM)
12.14%
Management effectiveness
Return on assets (TTM)
23.77%
Return on equity (TTM)
40.22%
Valuation
Price to earnings (TTM)
5.384
Price to revenue (TTM)
2.031
Price to book
2.06
Price to tangible book (TTM)
2.15
Price to free cash flow (TTM)
5.285
Free cash flow yield (TTM)
18.92%
Free cash flow per share (TTM)
1.014
Growth
Revenue change (TTM)
675.15%
Earnings per share change (TTM)
-168.74%
3-year revenue growth (CAGR)
64.31%
3-year earnings per share growth (CAGR)
-9.85%
What the Analysts think about CureVac
Analyst ratings (Buy, Hold, Sell) for CureVac stock.
Bulls say / Bears say
CureVac agreed to be acquired by BioNTech in a $1.25 billion all-stock deal, representing a 55% premium over its three-month average share price and positioning it within a larger oncology-focused mRNA leader. (Reuters)
Under a settlement with Pfizer and BioNTech, CureVac and GSK will receive $740 million upfront plus single-digit royalties on U.S. COVID-19 vaccine sales, bolstering its cash position and validating its mRNA intellectual property estate. (Reuters)
CureVac’s shares jumped 27% to a five-month high upon the announcement of the BioNTech deal, reflecting strong investor confidence in the strategic synergies and upside potential of the combined company. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CureVac Financial Performance
Revenues and expenses
CureVac Earnings Performance
Company profitability
CureVac News
AllArticlesVideos
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
Accesswire2 months ago
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
Proactive Investors2 months ago
CureVac settles patent dispute litigation with Pfizer and BioNTech
Reuters2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $1.2B as of October 15, 2025.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 5.38 as of October 15, 2025.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of October 15, 2025.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.